^
Association details:
| Biomarker: | STRN-NTRK2 fusion |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
Published date:
10/22/2023
Excerpt:
In-house next-generation sequencing gene fusion panel showed two in-frame STRN-NTRK2 fusions...After 130 days, larotrectinib was reinitiated for lung metastasis (up to 7 cm), and a complete resolution was achieved.
DOI:
10.1186/s13000-023-01400-1
